<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Misra-Press, Anita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Schuler, Martin</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">LUX-Lung 5</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-05-19 09:31:56</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-14</style></pages><abstract><style  face="normal" font="default" size="100%">LUX-Lung 5 is the first prospective randomized, phase 3 trial to demonstrate superior progression-free survival by continuing afatinib plus paclitaxel as fourth-line treatment vs single-agent chemotherapy in patients with non–small cell lung cancer who had disease progression on chemotherapy with the combination of erlotinib plus gefitinib and with afatinib monotherapy with a manageable safety profile.</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>